ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Public ClinicalTrials.gov record NCT03338816. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Study identification
- NCT ID
- NCT03338816
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- Givosiran Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2017
- Primary completion
- Jan 30, 2019
- Completion
- May 30, 2021
- Last update posted
- Apr 21, 2024
2017 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Little Rock | Arkansas | 72205 | — |
| Clinical Trial Site | San Francisco | California | 94143 | — |
| Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| Clinical Trial Site | Ann Arbor | Michigan | 48109 | — |
| Clinical Trial Site | New York | New York | 10029 | — |
| Clinical Trial Site | Winston-Salem | North Carolina | 27157 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19107 | — |
| Clinical Trial Site | Galveston | Texas | 77555 | — |
| Clinical Trial Site | Salt Lake City | Utah | 84112 | — |
| Clinical Trial Site | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03338816, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03338816 live on ClinicalTrials.gov.